| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | StAR-related lipid transfer protein 13, 46H232, Deleted in liver cancer 2 protein, DLC-2, Rho GTPase-activating protein, START domain-containing protein 13, StARD13, STARD13, DLC2, GT650 |
| Entrez GeneID | 90627 |
| WB Predicted band size | 125.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This STARD13 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 544-573 amino acids from the Central region of human STARD13. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于STARD13(DLC1)抗体的参考文献及其摘要概括：
1. **文献名称**：*"DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma"*
**作者**：Yuan BZ et al.
**摘要**：本研究利用STARD13(DLC1)抗体进行免疫组化分析，发现肝癌组织中DLC1表达显著缺失，证实其作为抑癌基因通过调控Rho GTP酶活性抑制肿瘤生长和转移。
2. **文献名称**：*"STARD13/DLC1 coordinates cancer cell invasion through RhoA/ROCK signaling pathway"*
**作者**：Heering J et al.
**摘要**：通过Western blot和免疫荧光技术(使用STARD13抗体)，作者发现STARD13通过抑制RhoA/ROCK通路调控乳腺癌细胞侵袭能力，其表达缺失促进肿瘤转移。
3. **文献名称**：*"Epigenetic inactivation of DLC1 in colorectal cancer: clinical and mechanistic implications"*
**作者**：Peng Z et al.
**摘要**：该研究使用STARD13抗体检测结直肠癌样本，发现DLC1因启动子甲基化而表达下调，并通过体外实验证明其恢复表达可抑制肿瘤迁移和侵袭。
4. **文献名称**：*"DLC1 interaction with non-muscle myosin IIA regulates cell migration and adhesion"*
**作者**：Liao YC et al.
**摘要**：利用STARD13抗体进行共聚焦显微镜分析，揭示DLC1通过与肌球蛋白IIA互作调控细胞骨架重组，影响细胞迁移和粘附功能。
以上文献均通过STARD13抗体验证蛋白表达或定位，并探讨其在肿瘤抑制、细胞迁移等生物学过程中的作用机制。
STARD13 (Steroidogenic Acute Regulatory Protein-Related Lipid Transfer Domain-Containing Protein 13), also known as DLC-2 (Deleted in Liver Cancer 2), is a member of the STARD family of GTPase-activating proteins (GAPs) that regulate Rho GTPase signaling pathways. It functions as a tumor suppressor by modulating cytoskeletal dynamics, cell migration, and proliferation. STARD13 contains a central lipid-binding START domain and a RhoGAP domain, which facilitates its role in inhibiting oncogenic RhoA/ROCK signaling. Dysregulation of STARD13 has been implicated in various cancers, including hepatocellular carcinoma, breast cancer, and colorectal cancer, where its downregulation correlates with tumor progression and metastasis.
The STARD13 (Center) antibody is a polyclonal or monoclonal reagent specifically designed to target the central region of the STARD13 protein. It is commonly used in Western blotting, immunofluorescence, and immunohistochemistry to detect endogenous STARD13 expression in cell lines and tissues. This antibody aids in studying STARD13's functional roles in cancer biology, epithelial-mesenchymal transition (EMT), and cellular signaling. Validation typically includes knockout cell line controls to confirm specificity. Researchers utilize this tool to explore STARD13's tumor-suppressive mechanisms, its interaction partners, and potential therapeutic applications in malignancies linked to Rho pathway dysregulation.
×
